Abstract: The application discloses methods of ensuring pelvic health and/or treating a disease or disorder characterized by a dysfunctional autonomous nervous system in a subject with neuromodulation. The methods are characterized by the application of a burst stimulation pattern comprising a plurality of groups of electric pulses of high frequencies to the subject.

Abstract: Provided herein are in vitro methods for diagnosing an immediate hypersensitivity reaction (IHR) against a small compound or a drug in a subject, comprising the steps of (a) contacting mast cells with serum obtained from said subject; (b) contacting the mast cells obtained in step (a) with said small compound or said drug; (c) detecting mast cell activation and/or degranulation of the mast cells obtained in step (b); and (d) attributing the detection or no detection of mast cell activation and/or degranulation to a particular diagnosis of IHR.

Abstract: The invention pertains to an ophthalmological device (100, 200) for the treatment of Limbal Stem Cell Deficiency, the device (100, 200) comprising: a stem cell carrier substrate; and a culture of limbal epithelial stem cells cultivated on said stem cell carrier substrate; wherein said stem cell carrier substrate comprises a hydrogel containing collagen or collagen-mimicking peptides; and wherein a ring-shaped area on a surface of said stem cell carrier substrate is provided with a pattern of niches (110, 210). The invention also pertains to a method for producing the ophthalmological device.

Abstract: The present invention relates to the field of combination immunotherapy, more in particular to a combination comprising IL-15 and a CD40 agonist for use in the treatment of cancer, such as and not limited to, pancreatic cancer (e.g. pancreatic ductal adenocarcinoma and pancreatic neuro-endocrine tumours).

Abstract: Method (100) for determining an immune responsiveness to a query epitope (126) comprising: receiving sequence data (122) comprising TCR sequences of at least a part of a TCR repertoire of a subject; selecting a predictive model (160) generated or trained using a dataset comprising TCR sequences known to bind specifically to a model epitope, said predictive model selected according to a sequence match between the model epitope and query epitope; querying (130) the selected predictive model (160) with the sequence data (122); determining (140) from outputs of the selected predictive model (160) a Responsiveness Score indicative of the immune responsiveness. The immune responsiveness can be used to predict and optimal vaccine composition and/or evaluate efficacy of a vaccine in a subject or population.

Abstract: The present invention relates to compounds having a benzotropolone core, and compositions containing said compounds acting as ATG4B inhibitors, thereby inhibiting autophagy. Moreover, the present invention provides processes for the preparation of the disclosed compounds, as well as methods of using them, for instance as a medicine, in particular for the treatment of cell proliferative disorders, such as cancer.